Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis. - Wang, Xinyue; Li, Zhaona; Wang, Liuchun; Liang, Yan; Huang, Chun; Chen, Peng; Huang, Dingzhi; Song, Xia; Ding, Cuimin; Wang, Changli; Jiang, Richeng (BMC Medicine, 2025)